BiotechTube
Attune Neurosciences

Attune Neurosciences

San Diego, United States· Est.
attuneneuro.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Attune Neurosciences is pioneering a new category of neuromodulation with its wearable, non-invasive ultrasound system designed for deep brain stimulation. The technology integrates MRI guidance for precision and adaptive algorithms to personalize therapy, targeting a range of neurological disorders. As a private, early-stage company, Attune is positioned to address significant unmet needs in neurology and psychiatry. Its success hinges on clinical validation, regulatory navigation, and establishing a clear advantage over existing invasive and non-invasive brain stimulation modalities.

NeurologyPsychiatry

Technology Platform

Wearable, non-invasive focused ultrasound system for deep brain stimulation, integrated with MRI-guided targeting and adaptive stimulation algorithms.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

The platform addresses a large unmet need for non-invasive, deep brain stimulation, potentially expanding treatable patient populations beyond those eligible for surgery.
The wearable format could enable chronic, at-home therapy, creating a new paradigm in disease management.
Success in one indication could allow rapid platform expansion into multiple neurological and psychiatric conditions.

Risk Factors

Substantial technical risk in developing a reliable, safe, and effective wearable ultrasound system capable of precise deep brain targeting.
High clinical and regulatory risk in proving efficacy and securing FDA approval for a novel Class III medical device.
Facing competition from established invasive DBS companies and improving non-invasive TMS technologies.

Competitive Landscape

Attune competes in the neuromodulation space against incumbent invasive Deep Brain Stimulation (DBS) systems from Medtronic, Boston Scientific, and Abbott. It also faces competition from non-invasive technologies like Transcranial Magnetic Stimulation (TMS) and emerging transcranial focused ultrasound (tFUS) research devices. Its key differentiator is the proposed combination of non-invasiveness, deep penetration, and a wearable, adaptive format.

More companies in Neuroscience & CNS →More companies in United States →